MedTrace Logo

GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

NCT01825148 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2014-12-02

No results posted yet for this study

Summary

The purpose of the study is to determine whether there are differences in pancreatic uptake of the radiotracer between healthy individuals and patients with type 1 diabetes. If T1D patients have a markedly reduced uptake, the compound may be suitable for estimation of pancreatic beta cell mass, i.e. the cells in the pancreas that produce insulin.

Conditions

Interventions

OTHER

radiolabeled Exendin

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01825148 on ClinicalTrials.gov